Medicine

Molecular profiling of BRAF-V600E-mutant metastatic colon cancer cells in the phase\u00e2 $ 3 LIGHTHOUSE CRC trial

.Competing passions.S.K.: Inventory as well as Various Other Possession Interests: Iylon, Lutris, MolecularMatch, Navire. Consulting or even Advisory Duty: AbbVie, Amal Therapies, AstraZeneca/MedImmune, Bayer Wellness, Bicara Rehabs, Boehringer Ingelheim, Boston Ma Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Effort BioMedicines, Fire Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Stone Healthcare, Inivata, Ipsen, Iylon, Jacobio, Jazz Drugs, Lilly, Lutris, Merck, Mirati Therapeutics, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Therapy, Servier, Xilis. Research Study Funding: Amgen (Inst), Variety BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Health (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Employment: Previously Pfizer. Inventory as well as Other Ownership Passions: Pfizer. J.P.: Job: Formerly Pfizer. Inventory and also Other Ownership Stakes: Pfizer. F.C.: Consulting or Advisory Job: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Investigation Funding: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or Advisory Job: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Analysis Backing: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or even Advisory Job: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Drug, Terumo. H.S.W.: Consulting or Advisory Function: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapies, Erytech Pharma, Incyte, Merck KGaA, Oaktree Life Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, Shire, Sirtex Medical, Takeda (Hutchinson Medication), Zymeworks. Research Study Backing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo Corp., Takeda. Study Backing: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Health, MSD (Inst), Nippon Boehringer Ingelheim, Ono Pharmaceutical (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Drug (Inst). H.S.: Employment: Pfizer. Sell as well as Other Ownership Stakes: Pfizer. X.Z.: Job: Pfizer. Assets and Other Ownership Stakes: Pfizer. Patents, Aristocracies, Other Copyright: Johns Hopkins University. P.H.: Employment: Pfizer. Inventory and also Other Possession Interests: Pfizer. T.X.: Work: Pfizer. Inventory as well as Various Other Ownership Interests: Pfizer. R.Y.: Consulting or even Advisory Job: Array BioPharma/Pfizer, Mirati Therapeutics, Zai Lab, Amgen. Research Study Funding: Selection BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Therapy (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or Advisory Part: Array BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Rehabs, MSD, NeoPhore, Novartis, Ona Therapeutics, Orion Medical, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Rehab, Seagen Inc., Servier, Taiho Drug, Tessa Rehab, TheraMyc. Other Partnership: Amgen, Range Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Cells Research UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de la Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Contra el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Health And Wellness KGaA, MJH Lifestyle Sciences, MSD, Merus, Mirati, Novartis, Oniria Therapies, PeerView Institute for Medical Education And Learning, Pfizer, PharmaMar, Physicansu00e2 $ Education Resource, Sanofi-Aventis, Servier, Taiho Drug.